Please login to the form below

bosentan

This page shows the latest bosentan news and features for those working in and with pharma, biotech and healthcare.

J&J agrees $30bn deal to acquire Actelion

Meanwhile, J&J claims the company's marketed products including its trio of pulmonary artery hypertension (PAH) drugs, including Tracleer (bosentan) - now facing generic competition - as well as follow-up drugs

Latest news

Actelion reports late-stage trial failure as J&J talks continue

Tracleer (bosentan) which has lost patent protection in the US and Europe. .
J&J back in frame to buy Actelion after Sanofi talks break down

Actelion has been through a difficult patch after losing patent protection for pulmonary artery hypertension (PAH) blockbuster Tracleer (bosentan), but is on the up with strong growth for follow-up PAH
J&J abandons talks with Actelion as another suitor circles

After a challenging couple of years following the loss of patent protection for pulmonary artery hypertension (PAH) blockbuster Tracleer (bosentan), Actelion is now riding high on the back of strong growth
Resurgent Actelion catches J&J's eye

Actelion's top-selling product Tracleer (bosentan) has already lost patent protection in some markets and saw sales slide 15% in the first nine months of the year to CHF 790m (
Actelion gets EU go-ahead for Uptravi in PAH

Tracleer (bosentan).

More from news
Approximately 3 fully matching, plus 20 partially matching documents found.

Latest appointments

J&J's Jane Griffiths named global head of Actelion

At that point it will gain marketed products that include a trio of pulmonary artery hypertension (PAH) drugs - Tracleer (bosentan), Opsumit (macitentan) and Uptravi (selexipag).
New associate director at Packer Forbes

Prior to this role she was a brand lead at pharma company Actelion where she spent several years on the marketing of hypertension treatment Tracleer (bosentan), during which time she worked

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Freelance Senior Account Manager / Account Director - Healthcare...: £350-400 depending on experience

Associate Director – Social Healthcare – London: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Programme/ Account Director - Healthcare PR - London: Salary TBC

Home based, Senior Medical Writer, Medical Communications: Excellent package

EU Head of Business Development and Client Service: Exceptional packge and bonus

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

AM – Corporate Comms/ Public Affairs/ B2B – Healthcare Focus: Salary TBC

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Scientific Director – Medical Communications: Salary TBC

Account Director, Healthcare Marketing Agency: Salary TBC

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Creative/ Medical Writer: Circa £35, 000 With Benefits

Home-based Medical Writer – Medical Education: Salary TBC

Account Director, Medical Education: Salary TBC

Senior Account Manager, Medical Communications, London: Excellent package

Senior Account Director – Healthcare Advertising – London: Salary TBC

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Senior Digital Health Specialist – Global Agency: Salary TBC

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Home-based Senior Medical Writer – Med Ed: Salary TBC

Senior Medical Writer: Salary TBC

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Managing Director – Global Medical Writing & Scientific Exce...: £120-150K

Health Consultant - Brand Comms: Competitive Salary

Freelance AM/ AD Healthcare Advertising: £350-400 depending on experience

Subscribe to our email news alerts

PMHub

Add my company

Digitas Health

Digitas Health is the only digital-at-the-core brand agency designed to connect today's healthcare brands with today's healthcare consumers and professionals....